蛋白药物与小分子药物相比具有高活性、高特异性、低毒性等优异特点，对不同肿瘤和自身免疫性疾病表现出很高的疗效。但是，临床上蛋白药物存在半衰期短、生物利用度较低、需要长期频繁注射给药等问题。免疫原性是蛋白药物临床应用常面临的另一个问题。我们将创新研究制备（i）生物可降解凝胶微球用于蛋白药物（如PD-1抗体、PD-L1抗体、赫赛汀、IL-2、IL-12等）的缓慢定点释放，实现肿瘤的高效免疫治疗，及（ii）生物可降解纳米凝胶和聚合物囊泡用于胞内蛋白药物（如胞内抗体、颗粒酶B、皂草素蛋白等）的肿瘤靶向递送，实现恶性肿瘤的高效蛋白治疗。

代表性论文

1)    K. Huang, Y.H. He, Z.H. Zhu, J.K. Guo, G.L. Wang, C. Deng*, and Z.Y. Zhong*, Small, Traceable, Endosome-Disrupting and Bioresponsive Click Nanogels Fabricated via Microfluidics for CD44-Targeted Cytoplasmic Delivery of Therapeutic Proteins, ACS Appl. Mater. Interfaces 2019, 11, 22171-22180.

2)    J. Chen, H. He, C. Deng*, L.C. Yin, and Z.Y. Zhong*, Saporin-Loaded CD44 and EGFR Dual-Targeted Nanogels for Potent Inhibition of Metastatic Breast Cancer In Vivo, Int. J. Pharmaceutics 2019, 560, 57-64.

3)    J. Chen, K. Huang, Q.J. Chen, C. Deng*, J. Zhang, and Z.Y. Zhong*, Tailor-Making Fluorescent Hyaluronic Acid Microgels via Combining Microfluidics and Photoclick Chemistry for Sustained and Localized Delivery of Herceptin in Tumor, ACS Appl. Mater. Interfaces 2018, 10, 3929-3937.

4)    D.C. Huang, H.L. Qian, H.S., Qiao, W. Chen*, J. Feijen, and Z.Y. Zhong*, Bioresponsive Functional Nanogels as An Emerging Platform for Cancer Therapy, Expert Opin. Drug Deliv. 2018, 15, 703-716.

5)    W.J. Yang, Y.H. Wei, J. Zhang, Z.Y. Zhong*, F.H. Meng*, Granzyme B-loaded, cell-selective penetrating and reduction-responsive polymersomes effectively inhibit progression of orthotopic human lung tumor in vivo, J. Control. Release 2018, 290, 141-149.

6)    M. Qiu, Z.Q. Zhang, Y.H. Wei, H.L. Sun, F.H. Meng, C. Deng*, and Z.Y. Zhong*, Small-Sized and Robust Chimaeric Lipopepsomes: A Simple and Functional Platform with High Protein Loading for Targeted Intracellular Delivery of Protein Toxin In Vivo, Chem. Mater. 2018, 30, 6831-6838.

7)    L. Cheng, Y. Yang, F.H. Meng*, Z.Y. Zhong*, Protein Nanotherapeutics as an Emerging Modality for Cancer Therapy, Adv. Healthcare Mater. 2018, 7, 1800685.